G. Poti

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide

E. Scarpi, V. Conteduca, U. de Giorgi, 2022, Cancers.

Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy

G. Martinelli, V. Conteduca, U. de Giorgi, 2021, Cancers.

Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC

A. Ceribelli, P. Marchetti, E. Ruggeri, 2018, AntiCancer Research.

Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome

E. Scarpi, P. Caroli, V. Conteduca, 2021, Molecular oncology.

Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging

P. Caroli, V. Conteduca, S. Russi, 2021, Therapeutic advances in medical oncology.